Video
Author(s):
OncLive’s December Roundup of Key FDA Approvals in Oncology
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
